The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for treating obesity. Unlike some retatrutide dosierung current weight loss treatments, retatrutide appears to deliver a significant substantial decrease in body weight and enhance